PharmaCyte Biotech, Inc. (PMCB) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

PharmaCyte Biotech, Inc. (PMCB) Healthcare & Pipeline Overview

PharmaCyte Biotech, Inc. is a US-based biotechnology firm developing advanced cellular therapies for cancer, diabetes, and malignant ascites. Utilizing its proprietary Cell-in-a-Box encapsulation technology, the company focuses on treatments for pancreatic cancer, Type 1 and insulin-dependent Type 2 diabetes, and cannabis-derived cancer therapies, supported by academic collaborations.

What Is the Investment Thesis for PMCB?

PharmaCyte Biotech, Inc. presents an investment thesis centered on its proprietary Cell-in-a-Box encapsulation technology and its application across multiple high-need therapeutic areas. The company's focus on advanced and inoperable pancreatic cancer, Type 1 and insulin-dependent Type 2 diabetes, and cannabis-derived cancer treatments targets markets with significant unmet medical needs. The Cell-in-a-Box platform, designed for localized and sustained cell delivery, represents a potential differentiator in cellular therapy. Key growth catalysts include the progression of its pipeline candidates through clinical trials, particularly for pancreatic cancer and diabetes, and any positive regulatory updates. Successful clinical outcomes could validate the technology and attract further investment or strategic partnerships. The company's collaborative agreements with the University of Technology, Sydney, and the University of Northern Colorado provide access to specialized research and development capabilities, potentially accelerating pipeline advancement. However, the company faces significant risks inherent in the biotechnology sector, including the high cost and uncertainty of clinical trial success, the stringent regulatory approval process, and the need for substantial ongoing financing. With a current market capitalization of $4.75M and a small operational team of 2 employees, the company's ability to execute its ambitious pipeline depends heavily on securing adequate funding and achieving positive clinical milestones. Investors should monitor trial results, regulatory submissions, and financing activities closely.

Based on FMP financials and quantitative analysis

PMCB Key Highlights

Proprietary Cell-in-a-Box Technology: Core platform utilizing cellulose encapsulation for live cell therapies targeting cancer and diabetes.

• Focused Therapeutic Pipeline: Developing treatments for advanced pancreatic cancer, Type 1 and insulin-dependent Type 2 diabetes, and cannabis-derived cancer therapies.
• Strategic Academic Collaborations: Partnerships with the University of Technology, Sydney, and the University of Northern Colorado to advance specific research areas.
• Small Market Capitalization: Currently valued at $0.01 billion, indicating a micro-cap company with significant potential volatility.
• Lean Operational Structure: Operates with 2 employees, reflecting a highly specialized and potentially outsourced R&D model.

Who Are PMCB's Competitors?

PMCB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are PMCB's Key Strengths?

Proprietary Cell-in-a-Box encapsulation technology offers a unique approach to cellular therapy.

• Focus on high-unmet-need therapeutic areas like advanced pancreatic cancer and diabetes.
• Established academic collaborations with the University of Technology, Sydney, and the University of Northern Colorado.
• Diverse pipeline including cell-based therapies and cannabis-derived treatments.

What Are PMCB's Weaknesses?

Very small operational team of 2 employees, potentially limiting internal R&D capacity and requiring extensive outsourcing.

• Micro-cap market capitalization ($4.75M) indicates limited financial resources and high reliance on external funding.
• Early-stage nature of pipeline means no current commercialized products or revenue generation.
• High dependence on successful clinical trial outcomes and regulatory approvals.

What Could Drive PMCB Stock Higher?

PMCB catalyst: Clinical Trial Updates for Pancreatic Cancer: Any announcements regarding the progress, interim data, or completion of clinical trials for their advanced pancreatic cancer treatment utilizing Cell-in-a-Box technology would be a significant catalyst.

• Regulatory Submissions and Approvals: Progress towards or submission of Investigational New Drug (IND) applications, or any subsequent regulatory filings for their pipeline candidates in the US, could signal advancement towards commercialization.
• Diabetes Therapy Development Milestones: Key developments or data readouts from the research and development efforts for their Type 1 and insulin-dependent Type 2 diabetes treatment, particularly concerning the melligen cells developed in collaboration with the University of Technology, Sydney.
• Partnership Developments: Any new or expanded strategic partnerships, licensing agreements, or collaborations that could provide additional funding, expertise, or accelerate the development and commercialization of their cellular therapies.
• Financing and Funding Rounds: Successful completion of financing rounds or securing grants that provide the necessary capital to sustain and advance their research and development pipeline.

What Are the Key Risks for PMCB?

Financial-distress signal — its Altman Z-Score of -2.32 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-7.7%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical Trial Failures: The inherent risk that PharmaCyte's pipeline candidates, including those for pancreatic cancer and diabetes, may not demonstrate sufficient efficacy or safety in clinical trials, leading to delays or discontinuation of development.
• Regulatory Hurdles: Significant challenges in obtaining regulatory approvals from the U.S. Food and Drug Administration (FDA) due to the complex nature of cellular therapies and the stringent requirements for demonstrating safety and efficacy.
• Funding and Liquidity Challenges: As a development-stage biotechnology company with a small market capitalization and no current revenue streams, there is an ongoing risk of needing substantial additional capital to fund its extensive research and clinical development activities.
• Intense Competition: The biotechnology sector, especially in cancer and diabetes, is highly competitive with numerous large pharmaceutical and biotech companies developing similar or alternative advanced therapies, potentially limiting future market share.
• Reliance on Key Technology and Collaborations: High dependence on the success of its proprietary Cell-in-a-Box technology and the continued effectiveness of its academic collaborations, any disruption to which could severely impact its pipeline.

What Are the Growth Opportunities for PMCB?

• Advancement of Pancreatic Cancer Therapy: PharmaCyte's primary focus on advanced and inoperable pancreatic cancer represents a significant growth opportunity. Pancreatic cancer is notoriously aggressive with limited treatment options and a poor prognosis, indicating a high unmet medical need. The company's Cell-in-a-Box technology aims to provide a localized and sustained delivery of chemotherapy, potentially improving efficacy and reducing systemic side effects. Successful progression through clinical trials and eventual regulatory approval for this indication could unlock a substantial market, as current therapies often offer only marginal survival benefits. Specific market size and timelines for this opportunity are not provided in the source data.
• Development of Diabetes Treatment: The company's pipeline includes a treatment for Type 1 and insulin-dependent Type 2 diabetes, utilizing encapsulated, genetically modified insulin-producing cells. This addresses a vast and growing patient population globally, with millions suffering from these chronic conditions requiring lifelong insulin management. The collaboration with the University of Technology, Sydney, for melligen cells underscores a dedicated effort in this area. A successful cell-based therapy that can provide sustained insulin production could revolutionize diabetes management, offering a significant improvement over daily insulin injections. Specific market size and timelines for this opportunity are not provided in the source data.
• Exploration of Cannabis-Derived Cancer Treatments: PharmaCyte is developing cancer treatments derived from cannabis plant compounds, a burgeoning area of research with increasing scientific interest. The collaboration with the University of Northern Colorado focuses on identifying, separating, and quantifying these constituents, which is crucial for developing standardized and effective therapies. If successful, this could tap into a novel therapeutic modality for oncology, potentially offering new options for patients who have exhausted conventional treatments or are seeking alternative approaches. The market for cannabis-derived pharmaceuticals is nascent but growing rapidly. Specific market size and timelines for this opportunity are not provided in the source data.
• Broadening Cell-in-a-Box Platform Applications: The proprietary Cell-in-a-Box encapsulation technology is a versatile platform that could potentially be applied beyond the current pipeline. While presently focused on pancreatic cancer and diabetes, the technology's ability to enclose live cells for localized, sustained therapeutic delivery could be valuable for other solid cancerous tumors or a range of chronic diseases requiring continuous delivery of biological agents. Expanding the indications for which Cell-in-a-Box is developed could significantly broaden PharmaCyte's market reach and intellectual property portfolio, creating multiple revenue streams in the long term. Specific market size and timelines for this opportunity are not provided in the source data.
• Leveraging Strategic Collaborations and Partnerships: PharmaCyte's existing collaborations with the University of Technology, Sydney, and the University of Northern Colorado are critical assets. These partnerships provide access to specialized scientific expertise, research facilities, and potentially accelerate the development timeline for their pipeline candidates. Further strategic alliances with larger pharmaceutical companies, contract research organizations, or other biotech firms could provide essential funding, manufacturing capabilities, and commercialization infrastructure. Such partnerships are vital for a small company to navigate the capital-intensive and complex drug development process. Specific market size and timelines for this opportunity are not provided in the source data.

What Threats Does PMCB Face?

• High risk of clinical trial failures, which are common in biotechnology.
• Stringent and lengthy regulatory approval processes by health authorities.
• Intense competition from established pharmaceutical and biotechnology companies.
• Challenges in securing sufficient financing for ongoing research and development.
• Potential for intellectual property challenges or the emergence of superior competing technologies.

What Are PMCB's Competitive Advantages?

• Proprietary Cell-in-a-Box Technology: A unique cellulose-based encapsulation platform designed for localized and sustained delivery of live cells, differentiating it from conventional drug delivery methods.
• Specialized Therapeutic Focus: Targeting high-unmet-need areas like advanced pancreatic cancer and Type 1 diabetes with specific cellular therapy approaches.
• Academic Collaborations: Established partnerships with the University of Technology, Sydney, and the University of Northern Colorado, providing access to specialized research and expertise.
• Early-Stage Pipeline: Potential for significant intellectual property development and market exclusivity if clinical trials are successful and regulatory approvals are secured.

What Does PMCB Do?

PharmaCyte Biotech, Inc. is a biotechnology firm dedicated to the development and commercialization of advanced cellular therapies within the United States. Established in 1996, the company initially operated under the name Nuvilex, Inc. before rebranding as PharmaCyte Biotech, Inc. in January 2015, marking an evolution in its strategic focus. Headquartered in Las Vegas, Nevada, the company's core mission revolves around addressing significant unmet medical needs in therapeutic areas such as various forms of cancer, diabetes, and malignant ascites. Central to their innovative approach is Cell-in-a-Box, their proprietary encapsulation technology. This advanced platform utilizes cellulose to enclose live cells, designed to enable localized and sustained delivery of therapeutic agents or functions. This innovative technology serves as the foundational element for a diverse pipeline of treatments. Specifically, PharmaCyte is developing therapies for advanced and inoperable pancreatic cancer, as well as other solid cancerous tumors. Beyond oncology, the company's pipeline includes a treatment for Type 1 and insulin-dependent Type 2 diabetes, which involves the use of encapsulated, genetically modified insulin-producing cells. Furthermore, PharmaCyte is exploring novel cancer treatments derived from compounds found in the cannabis plant. To bolster its research and development efforts, PharmaCyte maintains strategic collaborative agreements with academic institutions. One such agreement is with the University of Technology, Sydney, focused on the creation of melligen cells, which are integral to their diabetes combatting strategy. Another collaboration is with the University of Northern Colorado, concentrating on advanced methods for identifying, separating, and quantifying cannabis constituents, critical for their cannabis-derived cancer therapy research. These partnerships underscore PharmaCyte's commitment to leveraging scientific expertise to advance its cellular therapy platforms.

What Products and Services Does PMCB Offer?

• Develops advanced cellular therapies for cancer, diabetes, and malignant ascites.
• Utilizes a proprietary encapsulation technology called "Cell-in-a-Box" to enclose live cells.
• Focuses on treatments for advanced and inoperable pancreatic cancer.
• Working on a treatment for Type 1 and insulin-dependent Type 2 diabetes using encapsulated insulin-producing cells.
• Researches cancer treatments derived from cannabis plant compounds.
• Maintains collaborative agreements with academic institutions for specific research areas.
• Aims to commercialize its cellular therapy products in the United States.

How Does PMCB Make Money?

• Research and Development: Primarily focused on the preclinical and clinical development of proprietary cellular therapies.
• Intellectual Property: Building and leveraging intellectual property around its Cell-in-a-Box encapsulation technology and specific therapeutic applications.
• Strategic Collaborations: Engaging in partnerships with academic institutions to advance specific research components of its pipeline.
• Future Commercialization: Aims to commercialize its developed therapies upon successful clinical trials and regulatory approvals, generating revenue from product sales.

What Industry Does PMCB Operate In?

PharmaCyte Biotech, Inc. operates within the highly specialized and competitive biotechnology industry, specifically focusing on cellular therapies. This sector is characterized by intense research and development, significant capital requirements, and a lengthy, high-risk regulatory approval process. The company's therapeutic targets—cancer and diabetes—represent two of the largest and most critical disease areas globally, driving substantial investment in novel treatments. The global market for cancer therapeutics is projected to continue expanding, fueled by increasing incidence rates and advancements in targeted therapies and immunotherapies. Similarly, the diabetes market is growing due to rising prevalence and the demand for more effective disease management solutions. PharmaCyte's Cell-in-a-Box technology positions it within the advanced cell therapy segment, which aims to overcome limitations of traditional drug delivery. While the industry is dominated by large pharmaceutical companies and established biotech firms, smaller players like PharmaCyte seek to carve out niches with innovative platform technologies and targeted pipeline candidates. The competitive landscape includes companies developing gene therapies, stem cell therapies, and other advanced biologics for similar indications. Success in this environment hinges on demonstrating superior efficacy, safety, and a clear path to regulatory approval and commercialization.

Who Are PMCB's Key Customers?

• Future patients suffering from advanced and inoperable pancreatic cancer.
• Individuals with Type 1 and insulin-dependent Type 2 diabetes seeking advanced treatment options.
• Oncology patients who may benefit from novel cannabis-derived cancer treatments.
• Healthcare providers and institutions seeking innovative cellular therapies for challenging diseases.

Company Profile

PharmaCyte Biotech, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Las Vegas, US. The company is led by CEO Joshua N. Silverman. PMCB has traded publicly since 2013.

PharmaCyte Biotech, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.32 places it in the distress zone, a signal of elevated financial risk.

Return on equity for PharmaCyte Biotech, Inc. stands at -7.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -5.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -92.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 12.33 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -46.1%, the inverse of the P/E and a quick read on earnings relative to price.

PMCB Valuation & Market Position

With a $4.75M market cap, PharmaCyte Biotech, Inc. sits in the micro-cap segment of the market. Relative to its peer group, PMCB's quantitative score of 31/100 is below the peer average of 77/100.

PharmaCyte Biotech, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 58.9% above estimates on average.

Over the past six months, PharmaCyte Biotech, Inc. insiders filed 8 SEC Form 4 transactions — 0 sales and 8 purchases. On net that is roughly 477K shares acquired (about $319K) — insiders putting money in tends to read as conviction.

PMCB Financials

PMCB Latest News

PMCB Analyst Consensus

PMCB MoonshotScore

PMCB Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources